

ASX Announcement

7 March 2025

ReNerve Receives Additional \$139,537 in R&D Tax Incentive Refund

ReNerve Limited (ASX:RNV) (“ReNerve” or “the Company”) is pleased to announce that it has received an additional tax refund of \$139,537 relating to the Research and Development (R&D) Tax Incentive program, based on an assessment of its overseas research and development activities. This amount is in addition to an initial \$377,069 that was received in September 2024, resulting in a total R&D refund of \$516,606.

ReNerve continues to advance its portfolio of peripheral nerve repair solutions. The Company's first product with FDA clearance, the NervAlign® Nerve Cuff™, is already available to surgeons treating transection, compression, and stump neuroma peripheral nerve injuries (PNI) in the US market.

The Company is now working to introduce its next peripheral nerve repair product, the NervAlign® Nerve Conduit™. Additionally, ReNerve is developing a third product, the NervAlign® Nerve Guide Matrix™, to replace damaged nerves. This will allow ReNerve to provide a full range of products to surgeons for the repair and replacement of peripheral nerves.

The Company is conducting a clinical study on the use of its NervAlign® Nerve Cuff™ in nerve repairs and expects to present the results of this study at the American College of Foot and Ankle Surgeons Conference taking place from March 27th to March 30th, 2025.

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick

CEO & Managing Director

ReNerve Ltd

+61 (03) 9482 3940

info@renerve.com.au

Jane Morgan

Investor & Media Relations

Jane Morgan Management

+61 (0) 405 555 618

info@janemorganmanagement.com.au

About ReNerve Limited

ReNerve Limited (ASX:RNV) is a medical device company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering products that seek to address significant unmet needs for patients with peripheral nerve damage – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry's Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff.



+61 (03) 9482 3940



157 Heidelberg Rd,
Northcote, VIC 3070



www.renerve.com.au